This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.

This study has been terminated.
(Study will need to be redesigned for improved efficacy.)
Information provided by (Responsible Party):
Carolina Neurosurgery & Spine Associates Identifier:
First received: October 24, 2011
Last updated: July 27, 2015
Last verified: July 2015
The objective of this pilot study is to determine if degenerative spinal disorders such as acute radiculopathy, myelopathy, stenosis, or disc and facet disease cause detectable alterations in Substance P levels in saliva, serum and cerebrospinal fluid. If this pilot study shows a correlation between Substance P levels and pain associated with degenerative spinal disorders, then a larger study will be initiated to determine the feasibility of using Substance P levels in the diagnosis and treatment of degenerative spinal disease.

Condition Intervention
Spinal Disease,
Spinal Radiculopathy,
Neurogenic Claudication
Other: treatment plan

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Substance P Neuropeptide Levels in Saliva, Serum and Cerebrospinal Fluid in Patients With Spinal Disease: A Pilot Study

Resource links provided by NLM:

Further study details as provided by Carolina Neurosurgery & Spine Associates:

Primary Outcome Measures:
  • Substance P Neuropeptide Levels in Saliva And Serum in Patients with Spinal Disease: A Pilot Study [ Time Frame: 2009-2014 ] [ Designated as safety issue: No ]
    Study was closed pending re-design at some future date to improve efficacy.

Biospecimen Retention:   Samples Without DNA
Blood, saliva and cerebrospinal fluid

Enrollment: 53
Study Start Date: July 2009
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Healthy volunteers
surgery for spinal radiculopathy Other: treatment plan
Data Collection Study
surgery for axial spine pain Other: treatment plan
Data Collection Study
myelography for spinal pain Other: treatment plan
Data Collection Study


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Undergoing spinal surgery for medically refractory spinal radiculopathy,
  • myelopathy or neurogenic claudication based on either history, physical examination or radiologic studies demonstrating neural compression or degenerative disc disease.
  • Undergoing surgery for medically refractory axial spinal pain.

Exclusion Criteria:

  • Previous spinal procedures or operations,
  • radicular pain,
  • history of fibromyalgia,
  • chronic pain,
  • rheumatoid arthritis,
  • autoimmune disorders,
  • HIV,
  • PTSD,
  • Major Depressive Disorder,
  • migraine headaches or active rhinosinusitis,
  • nicotine intake
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01458938

United States, North Carolina
Carolina Neurosurgery and Spine Associates, P.A.
Charlotte, North Carolina, United States, 28204
Sponsors and Collaborators
Carolina Neurosurgery & Spine Associates
Principal Investigator: Vinay Deshmukh, M.D. Carolina Neurosurgery & Spine Associates
  More Information

No publications provided

Responsible Party: Carolina Neurosurgery & Spine Associates Identifier: NCT01458938     History of Changes
Other Study ID Numbers: Substance P
Study First Received: October 24, 2011
Last Updated: July 27, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Diseases
Substance P
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 27, 2015